NCT06511895

AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)

A Phase II, Open-Label, Single-Arm Study to Investigate the Safety, Tolerability, and Anti-tumor Activity of AZD4205 Treating Relapsed or Refractory Peripheral T Cell Lymphoma (r/r PTCL)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 57 (actual)
• Sponsor: Dizal Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase II, open label, multicenter study of AZD4205 administered orally in participants with r/r PTCL to determine its safety, tolerability, PK, and anti-tumor activity. Eligible participants are those who had pathologically confirmed PTCL and have relapsed after or been refractory/intolerant to at least one prior systemic treatment regimen. The primary objective of this study is to evaluate anti-tumor efficacy of AZD4205 at 150 mg once daily (RP2D) in participants with r/r PTCL. The safety, tolerability, and PK of AZD4205 in r/r PTCL at RP2D will also be investigated.

Conditions

• Peripheral T Cell Lymphoma

Interventions

Type	Name	Description
DRUG	AZD4205	AZD4205 capsules administered at 150 mg or 75 mg orally, once daily, in 28-day cycle.

Timeline

• Start date: 2022-05-31
• Primary completion: 2025-10-17
• Completion: 2025-10-17
• First posted: 2024-07-22
• Last updated: 2025-12-24

Locations

19 sites across 1 country: China